WW International, Inc. (NASDAQ:WW) reported Thursday first-quarter fiscal 2026 revenue of $168.3 million, down 9.8% year over year from $186.6 million, but above the $158.6 million analyst estimate.

• WW International shares are retreating from recent levels. What’s pressuring WW stock?

The company posted a GAAP net loss of $52 million, or $5.20 per share, compared with a net loss of $72.6 million, or 91 cents per share, a year earlier. EPS missed the analyst estimate of $(2.51).

Shares traded lower following the results. Adjusted EBITDA was a loss of $1.8 million versus the positive adjusted EBITDA of $26.9 million a year earlier.

Clinical Growth Offsets Behavioral Weakness

Clinical subscription revenue rose 32% year-over-year to $38.8 million, while clinical subscribers increased 46% to 197,000 despite lapping prior-year compounded semaglutide demand.

Total subscribers fell 22.6% to 2.66 million, with behavioral subscribers down 25.4% to 2.46 million. Behavioral subscription revenue declined 17.5% to $128.5 million amid weakness in the Core membership ...